

Andrew L Mason

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2619900/publications.pdf>

Version: 2024-02-01

154
papers

11,468
citations

38742

50
h-index

30087

103
g-index

156
all docs

156
docs citations

156
times ranked

11324
citing authors

#	ARTICLE	IF	CITATIONS
1	Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2. <i>Nature Chemical Biology</i> , 2022, 18, 81-90.	8.0	141
2	Metagenomics Versus Metatranscriptomics of the Murine Gut Microbiome for Assessing Microbial Metabolism During Inflammation. <i>Frontiers in Microbiology</i> , 2022, 13, 829378.	3.5	15
3	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	3.7	21
4	Vitamin D Is Associated with Clinical Outcomes in Patients with Primary Biliary Cholangitis. <i>Nutrients</i> , 2022, 14, 878.	4.1	8
5	Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis. <i>Viruses</i> , 2022, 14, 516.	3.3	3
6	Mass Spectrometry-Based Shotgun Glycomics Using Labeled Glycan Libraries. <i>Analytical Chemistry</i> , 2022, 94, 4997-5005.	6.5	4
7	Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis. <i>Hepatology</i> , 2022, 76, 303-316.	7.3	6
8	Isolation of a Human Betaretrovirus from Patients with Primary Biliary Cholangitis. <i>Viruses</i> , 2022, 14, 886.	3.3	7
9	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	4.4	30
10	Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. <i>Canadian Liver Journal</i> , 2021, 4, 401-425.	0.9	1
11	Combination antiretroviral therapy improves recurrent primary biliary cholangitis following liver transplantation. <i>Liver International</i> , 2021, 41, 1879-1883.	3.9	9
12	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021, 75, 572-581.	3.7	62
13	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	4.4	57
14	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	4.4	17
15	De novo and recurrent liver disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 46-47, 101688.	2.4	1
16	Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants. <i>Frontiers in Microbiology</i> , 2020, 11, 1653.	3.5	13
17	Case report: progressive familial intrahepatic cholestasis type 3 with compound heterozygous ABCB4 variants diagnosed 15 years after liver transplantation. <i>BMC Medical Genetics</i> , 2020, 21, 238.	2.1	4
18	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.4	74

#	ARTICLE	IF	CITATIONS
19	Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. <i>Hepatology Communications</i> , 2020, 4, 1332-1345.	4.3	28
20	Seroprevalence of Human Betaretrovirus Surface Protein Antibodies in Patients with Breast Cancer and Liver Disease. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	1.3	6
21	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2295-2304.e2.	4.4	18
22	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	3.7	47
23	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020, 69, 1502-1509.	12.1	28
24	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	1.6	2
25	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1127-1136.	3.7	66
26	Cirrhosis and Autoimmune Liver Disease. <i>Current Hepatology Reports</i> , 2019, 18, 49-58.	0.9	0
27	Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis. <i>Canadian Liver Journal</i> , 2019, 2, 31-44.	0.9	11
28	Self-reported experiences of patients living with primary biliary cholangitis (PBC): Are we treating the liver but not the patient?. <i>Canadian Liver Journal</i> , 2019, 2, 45-47.	0.9	1
29	Reply. <i>Gastroenterology</i> , 2019, 156, 2354-2355.	1.3	1
30	The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study. <i>Frontiers in Immunology</i> , 2019, 10, 662.	4.8	21
31	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	4.4	54
32	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 357-365.	3.7	148
33	Fibroblast Growth Factor 2 Enhances Zika Virus Infection in Human Fetal Brain. <i>Journal of Infectious Diseases</i> , 2019, 220, 1377-1387.	4.0	23
34	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 446-452.	0.4	65
35	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. <i>Gastroenterology</i> , 2019, 156, 96-107.e1.	1.3	82
36	Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 173-182.	3.7	46

#	ARTICLE	IF	CITATIONS
37	New perspectives on the complexity of genetic predisposition to autoimmune liver disease in indigenous Canadians. <i>Liver International</i> , 2018, 38, 789-791.	3.9	5
38	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. <i>Hepatology</i> , 2018, 67, 1890-1902.	7.3	204
39	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.4	64
40	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	7.3	55
41	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	12.1	42
42	Human Fetal Astrocytes Infected with Zika Virus Exhibit Delayed Apoptosis and Resistance to Interferon: Implications for Persistence. <i>Viruses</i> , 2018, 10, 646.	3.3	47
43	Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study. <i>CMAJ Open</i> , 2018, 6, E664-E670.	2.4	12
44	Is PBC a viral infectious disease?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 27-39.	2.4	14
45	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	1.3	355
46	Transmission of hepatitis D virus between spouses: A longitudinal study of the first reported Canadian case. <i>IDCases</i> , 2017, 8, 37-41.	0.9	4
47	Systematic review: recurrent autoimmune liver diseases after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 485-500.	3.7	93
48	Recurrence of primary biliary cholangitis after liver transplantation: A Japanese perspective. <i>Hepatology Communications</i> , 2017, 1, 391-393.	4.3	8
49	Effect of Oral Capsule vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent <i>Clostridium difficile</i> Infection. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1985.	7.4	446
50	Characterization of the Gut Microbiome Using 16S or Shotgun Metagenomics. <i>Frontiers in Microbiology</i> , 2016, 7, 459.	3.5	659
51	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	12.1	139
52	Mucosal Barrier Depletion and Loss of Bacterial Diversity are Primary Abnormalities in Paediatric Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 462-471.	1.3	178
53	Cerebrospinal Fluid in a Small Cohort of Patients with Multiple Sclerosis Was Generally Free of Microbial DNA. <i>Frontiers in Cellular and Infection Microbiology</i> , 2016, 6, 198.	3.9	9
54	Combination antiretroviral studies for patients with primary biliary cirrhosis. <i>World Journal of Gastroenterology</i> , 2016, 22, 349.	3.3	17

#	ARTICLE	IF	CITATIONS
55	Pericentriolar Targeting of the Mouse Mammary Tumor Virus GAG Protein. PLoS ONE, 2015, 10, e0131515.	2.5	8
56	Time to Make the Change from “Primary Biliary Cirrhosis” to “Primary Biliary Cholangitis”. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 293-293.	1.9	9
57	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. Gastroenterology, 2015, 148, 751-761.e8.	1.3	470
58	Role of Novel Retroviruses in Chronic Liver Disease: Assessing the Link of Human Betaretrovirus with Primary Biliary Cirrhosis. Current Infectious Disease Reports, 2015, 17, 460.	3.0	13
59	Frequent proviral integration of the human betaretrovirus in biliary epithelium of patients with autoimmune and idiopathic liver disease. Alimentary Pharmacology and Therapeutics, 2015, 41, 393-405.	3.7	31
60	Editorial: betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease “ authors” reply. Alimentary Pharmacology and Therapeutics, 2015, 41, 491-491.	3.7	1
61	Impact of combination antiretroviral therapy in the NOD .c3c4 mouse model of autoimmune biliary disease. Liver International, 2015, 35, 1442-1450.	3.9	19
62	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149, 1804-1812.e4.	1.3	330
63	Mitochondriome and Cholangiocellular Carcinoma. PLoS ONE, 2014, 9, e104694.	2.5	12
64	PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC). PLoS ONE, 2014, 9, e112877.	2.5	57
65	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	1.3	365
66	Letter: biochemical response to combination anti-retroviral therapy in patients with primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics, 2014, 39, 236-237.	3.7	6
67	The Genetics of Complex Cholestatic Disorders. Gastroenterology, 2013, 144, 1357-1374.	1.3	126
68	Systematic investigation of elevated cholestatic enzymes during the third posttransplant month. Liver Transplantation, 2013, 19, S23-S30.	2.4	9
69	Intrahepatic cholestasis in common chronic liver diseases. European Journal of Clinical Investigation, 2013, 43, 1069-1083.	3.4	49
70	Liver transplantation for overlap syndromes of autoimmune liver diseases. Liver International, 2013, 33, 210-219.	3.9	39
71	Is there a Role for Cyclophilin Inhibitors in the Management of Primary Biliary Cirrhosis?. Viruses, 2013, 5, 423-438.	3.3	5
72	Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: A 13-year experience. Liver Transplantation, 2013, 19, 611-618.	2.4	33

#	ARTICLE	IF	CITATIONS
73	A Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. <i>Annals of Hepatology</i> , 2013, 12, 282-293.	1.5	15
74	Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. <i>Annals of Hepatology</i> , 2013, 12, 282-293.	1.5	6
75	Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012, 21, 5209-5221.	2.9	139
76	Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. <i>Genes and Immunity</i> , 2012, 13, 328-335.	4.1	78
77	Incidence and risk factors associated with <i>de novo</i> autoimmune hepatitis after liver transplantation. <i>Liver International</i> , 2012, 32, 1426-1433.	3.9	42
78	Mouse Mammary Tumor Virus in Human Breast Cancer. <i>American Journal of Pathology</i> , 2011, 179, 1588-1590.	3.8	41
79	The evidence supports a viral aetiology for primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2011, 54, 1312-1314.	3.7	32
80	Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models. <i>Journal of Hepatology</i> , 2011, 55, 876-884.	3.7	32
81	The Impact of Sirolimus on hepatitis C Recurrence after Liver Transplantation. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011, 25, 28-34.	1.7	42
82	Lessons Learned from Liver Transplantation with the Canadian First Nations. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011, 25, 305-306.	1.7	3
83	Cyclosporine A inhibits in vitro replication of betaretrovirus associated with primary biliary cirrhosis. <i>Liver International</i> , 2010, 30, 871-877.	3.9	22
84	Linking human beta retrovirus infection with primary biliary cirrhosis. <i>Gastroenterologie Clinique Et Biologique</i> , 2010, 34, 359-366.	0.9	21
85	Cyclosporine A Protects Against Primary Biliary Cirrhosis Recurrence After Liver Transplantation. <i>American Journal of Transplantation</i> , 2010, 10, 852-858.	4.7	79
86	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010, 42, 658-660.	21.4	389
87	Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010, 42, 655-657.	21.4	205
88	Mouse retroviruses and chronic fatigue syndrome: Does X (or P) mark the spot?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15666-15667.	7.1	13
89	A Shorter Duration of Pre-Transplant Abstinence Predicts Problem Drinking After Liver Transplantation. <i>American Journal of Gastroenterology</i> , 2009, 104, 1700-1706.	0.4	89
90	Risk factors for recurrence of autoimmune hepatitis after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 1254-1261.	2.4	117

#	ARTICLE	IF	CITATIONS
91	The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver International, 2009, 29, 169-174.	3.9	40
92	Duplication of MER115 on chromosome 4 in patients with primary biliary cirrhosis. Liver International, 2009, 29, 375-383.	3.9	8
93	Primary biliary cirrhosis, bacteria and molecular mimicry: what's the molecule and where's the mimic?. Liver International, 2009, 29, 779-782.	3.9	16
94	Immunogenetic susceptibility to diabetes mellitus in patients with liver disease. Liver International, 2009, 29, 1543-1551.	3.9	6
95	Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants. New England Journal of Medicine, 2009, 360, 2544-2555.	27.0	569
96	Isolation of a human betaretrovirus resembling mouse mammary tumor virus (MMTV) from patients with primary biliary cirrhosis. Retrovirology, 2009, 6, P55.	2.0	3
97	Novel Approaches to Immunosuppression in Liver Transplantation. , 2009, , 19-44.		0
98	Metagenomics and the case of the deadly hamster. Hepatology, 2008, 48, 679-683.	7.3	2
99	Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Alimentary Pharmacology and Therapeutics, 2008, 28, 886-894.	3.7	52
100	Other Potential Medical Therapies: The Use of Antiviral Agents to Investigate and Treat Primary Ciliary Cirrhosis. Clinics in Liver Disease, 2008, 12, 445-460.	2.1	15
101	De Novo Sirolimus-Based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects. Transplantation, 2007, 83, 1162-1168.	1.0	165
102	New insights from recurrent primary biliary cirrhosis in liver transplantation: The paradox of BEComing a fibroblast?. Hepatology, 2007, 45, 837-840.	7.3	6
103	Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology, 2007, 46, 1836-1843.	7.3	30
104	Reverse transcriptase activity in patients with primary biliary cirrhosis and other autoimmune liver disorders. Alimentary Pharmacology and Therapeutics, 2007, 26, 587-595.	3.7	24
105	An autoimmune biliary disease mouse model for primary biliary cirrhosis: Something for everyone. Hepatology, 2006, 44, 1047-1050.	7.3	16
106	The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metabolism, 2006, 3, 321-331.	16.2	558
107	Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology Workshop. Canadian Journal of Gastroenterology & Hepatology, 2006, 20, 725-734.	1.7	5
108	Role of viral replication in extrahepatic syndromes related to hepatitis B virus infection. Minerva Gastroenterologica E Dietologica, 2006, 52, 53-66.	2.2	15

#	ARTICLE	IF	CITATIONS
109	Hepatitis B Virus Replication in Damaged Endothelial Tissues of Patients with Extrahepatic Disease. American Journal of Gastroenterology, 2005, 100, 972-976.	0.4	57
110	Pilot Studies of Single and Combination Antiretroviral Therapy in Patients with Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2004, 99, 2348-2355.	0.4	57
111	Proof of Principal Studies to Assess the Role of the Human Betaretrovirus in Patients with Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2004, 99, 2499-2500.	0.4	16
112	Primary biliary cirrhosis: Report of a focus study group. Hepatology, 2004, 40, 1013-1020.	7.3	29
113	Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology, 2004, 39, 151-156.	7.3	104
114	Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplantation, 2004, 10, 1301-1311.	2.4	241
115	Patients with primary biliary cirrhosis make anti-viral and anti-mitochondrial antibodies to mouse mammary tumor virus. Gastroenterology, 2004, 127, 1863-1864.	1.3	27
116	Primary biliary cirrhosis: Report of a focus study group. Hepatology, 2004, 40, 1013-1020.	7.3	9
117	Treatment of recurrent hepatitis C in liver transplant recipients: Is there any histologic benefit?. Liver Transplantation, 2003, 9, 354-359.	2.4	19
118	Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors?. Liver Transplantation, 2003, 9, 1258-1264.	2.4	27
119	Is type II diabetes another extrahepatic manifestation of HCV infection?. American Journal of Gastroenterology, 2003, 98, 243-246.	0.4	20
120	Does a betaretrovirus infection trigger primary biliary cirrhosis?. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8454-8459.	7.1	225
121	Acute autoimmune hepatitis presenting with centrilobular liver disease: case report and review of the literature. American Journal of Gastroenterology, 2002, 97, 2670-2673.	0.4	74
122	Biologic effects of anti-retroviral therapy in patients with primary biliary cirrhosis. Journal of Hepatology, 2002, 36, 154.	3.7	0
123	Primary biliary cirrhosis: New thoughts on pathophysiology and treatment. Current Gastroenterology Reports, 2002, 4, 45-51.	2.5	27
124	Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology, 2002, 36, 150-155.	7.3	306
125	Pilot study of lamivudine for patients with primary biliary cirrhosis. Journal of Hepatology, 2001, 34, 205.	3.7	3
126	Steroid-free immunosuppression through thymoglobulin induction in liver transplantation. Transplantation Proceedings, 2001, 33, 1470-1471.	0.6	24

#	ARTICLE	IF	CITATIONS
127	AUTOIMMUNE LIVER DISEASE. Clinics in Liver Disease, 2001, 5, 287-314.	2.1	30
128	Viral Induction of Type 2 Diabetes and Autoimmune Liver Disease. Journal of Nutrition, 2001, 131, 2805S-2808S.	2.9	15
129	Steroid-free liver transplantation using rabbit antithymocyte globulin induction: Results of a prospective randomized trial. Liver Transplantation, 2001, 7, 693-697.	2.4	123
130	Transplantation of livers from HBc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. Clinical Transplantation, 2001, 15, 55-58.	1.6	36
131	Viruses and diabetes: is there something sweet about hepatitis C infection?. Ochsner Journal, 2001, 3, 158-63.	1.1	4
132	GP73, a novel Golgi-localized protein upregulated by viral infection. Gene, 2000, 249, 53-65.	2.2	226
133	Tt Virus: Will Work for Food?. American Journal of Gastroenterology, 1999, 94, 3398-3401.	0.4	0
134	Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology, 1999, 29, 328-333.	7.3	593
135	Hepatic manifestations of familial patent ductus venosus in adults. Gut, 1999, 45, 442-445.	12.1	43
136	Retroviruses in autoimmune liver disease: genetic or environmental agents?. Archivum Immunologiae Et Therapiae Experimentalis, 1999, 47, 289-97.	2.3	15
137	Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology, 1998, 27, 1736-1742.	7.3	198
138	Detection of retroviral antibodies in primary biliary cirrhosis. Lancet, The, 1998, 352, 739-740.	13.7	6
139	Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis. Lancet, The, 1998, 352, 1595-1596.	13.7	57
140	HERV-K10s and Immune-Mediated (Type 1) Diabetes. Cell, 1998, 95, 14-16.	28.9	38
141	Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet, The, 1998, 351, 1620-1624.	13.7	154
142	A case of syncytial giant cell hepatitis with features of a paramyxoviral infection. American Journal of Gastroenterology, 1998, 93, 1931-1937.	0.4	45
143	Co-existence of hepatitis A and adult Reye's syndrome.. Gut, 1997, 41, 121-124.	12.1	13
144	Hepatitis and cholestasis in a middle-aged woman. Hepatology, 1996, 24, 730-734.	7.3	22

#	ARTICLE	IF	CITATIONS
145	The A to Z of new hepatotropic agents: Human hepatitis viruses and monkey business. Liver Transplantation, 1996, 2, 395-405.	1.8	6
146	Hepatitis and cholestasis in a middle-aged woman. Hepatology, 1996, 24, 730-734.	7.3	2
147	What Causes Fulminant Hepatic Failure of Unknown Etiology?. American Journal of Clinical Pathology, 1995, 104, 491-494.	0.7	13
148	Genomic variations in the hepatitis B core gene: A possible factor influencing response to interferon alfa treatment. Gastroenterology, 1995, 108, 505-514.	1.3	65
149	Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology, 1993, 18, 781-789.	7.3	169
150	Intractable neurological Wilson's disease treated with orthotopic liver transplantation. Digestive Diseases and Sciences, 1993, 38, 1746-1750.	2.3	51
151	Hepatitis B and Liver Transplantation – Problems and Promises. New England Journal of Medicine, 1993, 329, 1885-1887.	27.0	39
152	Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology, 1993, 105, 237-244.	1.3	66
153	Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology, 1992, 103, 1649-1656.	1.3	132
154	Hepatitis B virus DNA in peripheral-blood mononuclear cells in chronic hepatitis B after HBsAg clearance. Hepatology, 1992, 16, 36-41.	7.3	93